Navigation Links
PLC Medical Systems Announces Publication of Care Study Update

FRANKLIN, Mass., July 16 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that a follow-up study of the landmark Cardiac Angiography in Renally Impaired Patients (CARE) Study determined that Contrast-Induced Nephropathy (CIN) is associated with long-term adverse events, ranging from pulmonary edema to death, and that patients with CIN were twice as likely as those who did not develop CIN to experience adverse events.

The study was published in the June 25, 2009 issue of the Clinical Journal of the American Society of Nephrology (CJASN). This study, authored by Dr. Richard J. Solomon, Professor of Medicine, University of Vermont College of Medicine,, followed more than 70 percent of the original subjects of the CARE study. Dr. Solomon is a member of the Scientific Advisory Board for PLC Medical Systems, and is one of the principal investigators for PLC's FDA-approved pivotal trial for RenalGuard in the U.S.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "CIN is a significant and growing concern worldwide, and the publication of this study adds scientific weight to the need to find a way of preventing it. We continue to be very encouraged by the work of scientists who are studying our RenalGuard System((R)), which we believe could be an effective solution in reducing the incidence rate of CIN."

Currently, RenalGuard((R)) is the subject of an investigator-sponsored trial to study its efficacy in mitigating against CIN at the University of Milan-Centro Cardiologico Monzino (CCM). This trial is designed to assess RenalGuard compared to standard overnight hydration, a prevalent method of treatment in the EU, in preventing CIN in patients undergoing cardiac catheterization procedures and percutaneous coronary interventions with baseline impairment in renal function.

PLC received the CE Mark Certificate for the RenalGuard System in December 2007 and concluded its pilot safety trial in the U.S. late in 2007. The company has received full approval from the FDA to commence a U.S. pivotal trial to study the effectiveness of RenalGuard in the prevention of CIN. In March 2008, PLC signed its first international distribution agreement for RenalGuard with Artech s.r.l., Cavezzo, Italy for distribution of its RenalGuard System in Italy, and in May 2009, PLC announced its second European distributor, IZASA Distribuciones Tecnicas S.A., headquartered in Barcelona, Spain, for the distribution of RenalGuard in Spain.

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, we may be unable to raise sufficient funds in the future to implement our business plan and/or commence our planned U.S. clinical trial for RenalGuard, the current clinical trial in Italy and the planned future U.S. clinical trial for RenalGuard as a safe and effective prevention device for contrast induced nephropathy may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2008, and our other SEC reports.

PLC Systems, PLC Medical Systems, PLC and CO2( )Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.

    Contact:  Mary T. Conway
    Conway Communications

SOURCE PLC Systems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. In Colorado, Commercial Medical and Pharmacy Benefit Enrollment Down at State Level
2. Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio
3. "Aprima Medical Software, Inc.," Unveiled by iMedica; Premier EHR / PM Company Adopts New Name
4. Tube Feeding Error: Fatal Medical Mistakes
5. Aprima Medical Software, Inc., Unveiled by iMedica; Premier EHR / PM Company Adopts New Name
6. Demand for Short-Term Medical Help Leads to Growth for Travel Nursing Staffing Agency; Prompts Move to New Location and Addition of New Online Tools for Nurses
7. Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
8. Bronx Jury Awards 60 Million Dollars to Woman in Medical Malpractice Case
9. MultiNational Underwriters Is Now HCC Medical Insurance Services
10. Marathon Health Adds Fitness Center Capability -- Medically-based Fitness Centers Show Improved Engagement and Efficacy
11. MedicAlert Foundation and Autism Society Launch New Program to Safeguard Individuals and Families Living With Autism
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... 2015 , ... World Patent Marketing , a vertically ... invention that provides an economical and easy way of gaining customized curtains. , ... 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "There ...
(Date:11/29/2015)... ... November 29, 2015 , ... ... Institute of Ultrasound in Medicine! , AIUM ultrasound practice accreditation is a ... or exceed nationally recognized standards in the performance and interpretation of diagnostic ...
(Date:11/29/2015)... Los Angeles, Ca (PRWEB) , ... November 29, 2015 , ... ... from the American Board of Ophthalmology on November 25th 2015. Peer Certification ... in the field of his specialty. Certification in Ophthalmology is first obtained after the ...
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target via ... “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a limited ... price. , IguanaMed’s mission is to outfit every healer around the world ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
(Date:11/30/2015)... , November 30, 2015 Elbit ... the "Company") announced today that it was informed by InSightec ... Drug Safety (MFDS) has approved its Exablate Neuro system ... --> --> Insightec,s Exablate Neuro ... alternative that combines two technologies: Focused Ultrasound, which is ...
(Date:11/29/2015)... CHICAGO , Nov. 29, 2015  The GE Health ... annual Radiological Society of North America ... exclusively for the healthcare industry, the new cloud ecosystem and ... and collaboration across care pathways and multidisciplinary teams – both ... Immelt , Chairman and CEO of GE. "As the digital ...
Breaking Medicine Technology: